{"id":"trivalent-opv-4-week-interval","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":"rare","effect":"Vaccine-associated paralytic poliomyelitis (VAPP) in immunocompromised recipients"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains three live attenuated poliovirus strains that replicate in the intestinal tract, stimulating both local intestinal immunity (IgA) and systemic immunity (IgG). This oral route of administration promotes mucosal tolerance and herd immunity, as vaccinated individuals shed attenuated virus that can immunize contacts. The 4-week interval dosing schedule allows for sequential immune priming and boosting across multiple doses.","oneSentence":"Trivalent OPV provides immunization against three serotypes of poliovirus (types 1, 2, and 3) by inducing mucosal and systemic immune responses through oral administration of live attenuated virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:48.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention (poliovirus types 1, 2, and 3)"}]},"trialDetails":[{"nctId":"NCT01633216","phase":"PHASE4","title":"Poliovirus Vaccine Trial in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Trivalent OPV 4 week interval","genericName":"Trivalent OPV 4 week interval","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Trivalent OPV vaccine was studied in a trial involving healthy infants, with the vaccine administered at a 4-week interval. The trial, titled \"Poliovirus Vaccine Trial in Bangladesh,\" aimed to assess the immunogenicity of the Trivalent OPV vaccine in this population.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}